28 February 2021 in Kardiologiia
Aim To compare the antihypertensive effectivity of renal denervation in patients with diabetes mellitus (DM) and associated refractory arterial hypertension (rfAH) (treated with 5 or more classes of antihypertensive drugs, including a thiazide diuretic and a mineralocorticoid receptor antagonist) and uncontrolled resistant AH (ucAH) (treated with 3-4 drugs). Material and methods This interventional study with renal denervation included 18 DM patients with rfAH and 40 DM patients with ucAH; 16 and 36 of them, respectively, completed the study in 6 months. At baseline, patients were sex- and age-matched. Study methods included measurement of office blood pressure (BP; systolic/diastolic BP, SBP/DBP); outpatient BP monitoring; evaluation of kidney function (estimated glomerular filtration rate by the CKD-EPI formula); diurnal diuresis volume; diurnal urinary excretion of albumin, potassium and sodium; diurnal excretion of metanephrines and normetanephrines; and plasma levels of glucose and glycated hemoglobin, aldosterone, and active renin. Patients were instructed about maintaining compliance with their antihypertensive and hypoglycemic therapy throughout the study. Results At baseline, patients of both groups were comparable by BP and major clinical indexes, except for higher values of nocturnal SBP variability (p<0.05) in patients with rfAH. At 6 months following renal denervation, both groups displayed significant decreases in office and average daily SBP and also in the “load” with increased mean diurnal SBP. However, the decrease in average daily SBP was almost 4 times greater in the rfAH group than in the ucAH group ( –19.9 and –5.1 mm Hg, respectively, р=0.02). Moreover, 81 % of patients in the rfAH group responded to the intervention (average daily SBP decrease ≥10 mm Hg) while the number of responders in the ucAH group was considerably smaller (42 %; p=0.02). In patients with rfAH, renal denervation was associated with a significant decrease in pulse BP and nocturnal SBP variability and with the increase in diurnal diuresis. No other alterations were noted in laboratory test results in either group. Conclusion DM patients with rfAH may be the best candidates for the procedure of renal denervation.
12 April 2020 in Siberian Journal of Clinical and Experimental Medicine
Ренальная денервация как новая стратегия нефропротекции у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа
25 January 2020 in Siberian Journal of Clinical and Experimental Medicine
Влияние ренальной денервации на уровень адипокинов и провоспалительный статус у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа
30 June 2024 in Kardiologiia
Aim . To evaluate the efficacy and safety of intracoronary epinephrine for the treatment of refractory no-reflow phenomenon in patients with ST-segment elevation myocardial infarction (STEMI) during percutaneous coronary intervention (PCI). Material and methods . A single-site prospective controlled study “Intracoronary administration of epinephrine for refractory no-reflow phenomenon in patients with acute myocardial infarction” was conducted (registration on ClinicalTrials.gov: NCT04573751). The study included 40 patients with refractory no-reflow phenomenon, which was identified when it was not resolved with at least one of the following means: nitroglycerin, adenosine, papaverine, platelet receptor inhibitors IIB/IIIA, or thromboaspiration. Patients were divided into 2 groups: patients of group 1 (n=18) were injected with intracoronary epinephrine 100 μg, patients of group 2 (n=22) received standard therapy without epinephrine. The groups did not differ in the main baseline clinical and anamnestic characteristics, with the exception of the predominance of men in the control group: 86.4% vs. 55.6% (p=0.03). Results. In the epinephrine group, TIMI 3 blood flow was more often achieved: 55.6% vs. 0% (p50% within 1 hour after PCI: 72.2% vs. 31.8% (p=0.01). Concentrations of troponin I 12-24 h after PCI were significantly lower in the epinephrine group than in the control group: 15.2 (6;25) ng/ml vs. 25 (10;40) ng/ml (p=0.03). No life-threatening hemodynamic disorders or cardiac arrhythmias were recorded after the administration of epinephrine. No statistically significant differences were found in cardiac ultrasound data and MACE (Major Adverse Cardiovascular Events) during 30 days of follow-up. Conclusions . Intracoronary epinephrine 100 μg in STEMI patients with refractory no-reflow phenomenon during PCI is a safe and effective method for improving the blood flow in the infarct-related coronary artery. The prevalence of refractory no-reflow phenomenon among STEMI patients in our study reached 4.6%.
9 April 2022 in Siberian Journal of Clinical and Experimental Medicine
Clinical examples for variants of cardiovascular complications of a new coronavirus infection (COVID-19) are presented when they are visualized by means of magnetic resonance imaging (MRI) of the heart and chest organs with paramagnetic contrast enhancement and synchronization with ECG and respiration signal. The syndromes of post-COVID focal infarct injury and diffuse inflammatory lesion are identified. The picture of MRI visualization of coronary atherosclerotic plaque is presented. The results of quantitative processing of cardiac MRI in these two different syndromes of post-COVID cardiological complications are presented. The presented clinical examples indicate the need for cardiac MRI to monitor patients and assess the long-term cardiovascular effects of COVID-19.
14 December 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Влияние ренальной денервации на МРТ-признаки повреждения сосудистой стенки у больных резистентной артериальной гипертензией в сочетании с сахарным диабетом 2-го типа